In a preclinical study in colorectal cancer cells with or without KRAS and PIK3CA mutations, the combination of ribociclib with alpelisib was more effective than each drug alone in vitro and in vivo in mice xenografts [46] (Table 3). The gene discussed is KRAS; the disease is colorectal cancer.